Stay updated on Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial

Sign up to get notified when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The clinical trial record for surufatinib, toripalimab, and chemotherapy in second-line colorectal cancer is displayed instead of an error page. It provides study design, eligibility requirements, contacts and location, and measured outcomes.
    Difference
    46%
    Check dated 2026-11-08T02:33:32.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T22:37:43.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A site-wide notice announces NIH website updates and says that “Super Intelligence” (SI) is being used in place of “Artificial Intelligence” (AI) during the transition.
    Difference
    1%
    Check dated 2026-10-24T22:35:12.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The site's displayed revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T22:52:50.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The site footer now displays revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-10T22:35:07.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study record, indicating restricted access to the study details.
    Difference
    18%
    Check dated 2026-09-19T22:28:52.000Z thumbnail image

Stay in the know with updates to Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.